These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31834804)

  • 1. Clinically Relevant OATP2B1 Inhibitors in Marketed Drug Space.
    Unger MS; Mudunuru J; Schwab M; Hopf C; Drewes G; Nies AT; Zamek-Gliszczynski MJ; Reinhard FBM
    Mol Pharm; 2020 Feb; 17(2):488-498. PubMed ID: 31834804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preincubation-dependent inhibition of organic anion transporting polypeptide 2B1.
    Sinokki A; Miinalainen A; Kiander W; Kidron H
    Eur J Pharm Sci; 2024 Sep; 200():106852. PubMed ID: 39019347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Food Additives as Inhibitors of Intestinal Drug Transporter OATP2B1.
    Tikkanen A; Pierrot E; Deng F; Sánchez VB; Hagström M; Koenderink JB; Kidron H
    Mol Pharm; 2020 Oct; 17(10):3748-3758. PubMed ID: 32845645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of Fluorescent Substrates and Substrate-Dependent Interactions of a Drug Transporter Organic Anion Transporting Polypeptide 2B1 (OATP2B1).
    Kawasaki T; Shiozaki Y; Nomura N; Kawai K; Uwai Y; Nabekura T
    Pharm Res; 2020 Jun; 37(6):115. PubMed ID: 32483763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of natural products as modulators of OATP2B1 using LC-MS/MS to quantify OATP-mediated uptake.
    Wen F; Shi M; Bian J; Zhang H; Gui C
    Pharm Biol; 2016; 54(2):293-302. PubMed ID: 25858254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential inhibition features of direct-acting anti-hepatitis C virus agents against human organic anion transporting polypeptide 2B1.
    Furihata T; Fu Z; Suzuki Y; Matsumoto S; Morio H; Tsubota A; Matsumoto S; Chiba K
    Int J Antimicrob Agents; 2015 Oct; 46(4):381-8. PubMed ID: 26163159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational Discovery and Experimental Validation of Inhibitors of the Human Intestinal Transporter OATP2B1.
    Khuri N; Zur AA; Wittwer MB; Lin L; Yee SW; Sali A; Giacomini KM
    J Chem Inf Model; 2017 Jun; 57(6):1402-1413. PubMed ID: 28562037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin.
    Johnson M; Patel D; Matheny C; Ho M; Chen L; Ellens H
    Drug Metab Dispos; 2017 Jan; 45(1):27-34. PubMed ID: 27737931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of 22 Antituberculosis Drugs for Inhibitory Interaction Potential on Organic Anionic Transporter Polypeptide (OATP)-Mediated Uptake.
    Parvez MM; Jung JA; Shin HJ; Kim DH; Shin JG
    Antimicrob Agents Chemother; 2016 May; 60(5):3096-105. PubMed ID: 26976869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Organic anion transporting polypeptide 2B1 - More than a glass-full of drug interactions.
    McFeely SJ; Wu L; Ritchie TK; Unadkat J
    Pharmacol Ther; 2019 Apr; 196():204-215. PubMed ID: 30557631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
    Elsby R; Martin P; Surry D; Sharma P; Fenner K
    Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3.
    Sato T; Ito H; Hirata A; Abe T; Mano N; Yamaguchi H
    Xenobiotica; 2018 Jan; 48(1):73-78. PubMed ID: 28005438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organic anion-transporting polypeptide (OATP) 2B1 contributes to the cellular uptake of theaflavin.
    Kondo A; Narumi K; Ogura J; Sasaki A; Yabe K; Kobayashi T; Furugen A; Kobayashi M; Iseki K
    Drug Metab Pharmacokinet; 2017 Apr; 32(2):145-150. PubMed ID: 28190756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fexofenadine and Rosuvastatin Pharmacokinetics in Mice with Targeted Disruption of Organic Anion Transporting Polypeptide 2B1.
    Medwid S; Li MMJ; Knauer MJ; Lin K; Mansell SE; Schmerk CL; Zhu C; Griffin KE; Yousif MD; Dresser GK; Schwarz UI; Kim RB; Tirona RG
    Drug Metab Dispos; 2019 Aug; 47(8):832-842. PubMed ID: 31123035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between crude drug extracts used in Japanese traditional Kampo medicines and organic anion-transporting polypeptide 2B1.
    Iijima R; Watanabe T; Ishiuchi K; Matsumoto T; Watanabe J; Makino T
    J Ethnopharmacol; 2018 Mar; 214():153-159. PubMed ID: 29248449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium-dependent transporter expressed in HEK293 cells.
    Taub ME; Mease K; Sane RS; Watson CA; Chen L; Ellens H; Hirakawa B; Reyner EL; Jani M; Lee CA
    Drug Metab Dispos; 2011 Nov; 39(11):2093-102. PubMed ID: 21849517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current understanding of hepatic and intestinal OATP-mediated drug-drug interactions.
    Koenen A; Kroemer HK; Grube M; Meyer zu Schwabedissen HE
    Expert Rev Clin Pharmacol; 2011 Nov; 4(6):729-42. PubMed ID: 22111859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-drug interaction between pitavastatin and various drugs via OATP1B1.
    Hirano M; Maeda K; Shitara Y; Sugiyama Y
    Drug Metab Dispos; 2006 Jul; 34(7):1229-36. PubMed ID: 16595711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
    Gao C; Zhang H; Guo Z; You T; Chen X; Zhong D
    Drug Metab Dispos; 2012 Oct; 40(10):2009-20. PubMed ID: 22822035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography.
    Bauer M; Matsuda A; Wulkersdorfer B; Philippe C; Traxl A; Özvegy-Laczka C; Stanek J; Nics L; Klebermass EM; Poschner S; Jäger W; Patik I; Bakos É; Szakács G; Wadsak W; Hacker M; Zeitlinger M; Langer O
    Clin Pharmacol Ther; 2018 Jul; 104(1):139-147. PubMed ID: 28940241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.